Benitec Q2 FY2026 net loss $11.8M; all Cohort 1 patients respond to BB-301 at 12 months

Benitec Biopharma Inc.

2026-Q2 EPS reported -$0.48

Net loss of $11.8M ($0.26 per share) vs $9.6M YoY; total expenses $13.4M (up from $10.8M).
All 4 Cohort 1 completers in BB-301 Phase 1b/2a met Responder criteria at 12-month follow-up.
Patient 1 showed deepening improvements in swallow function and dysphagia at 24 months.
Cash and equivalents $189M; FDA meeting mid-2026 to confirm pivotal study design for BB-301.
Cohort 2 interim results expected mid-2026; first patient dosed in Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.